William Blair analyst Sami Corwin has maintained their bullish stance on SLDB stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Sami Corwin has given his Buy rating due to a combination of factors that highlight Solid Biosciences’ promising developments and potential. The initial clinical update for SGT-003 has been particularly encouraging, demonstrating safety and efficacy, which are crucial for the company’s success. The observed microdystrophin expression in patients suggests a potential long-term benefit, while the biomarker data indicating improved muscle and cardiac function are considered impressive and unprecedented.
Additionally, the ongoing dosing in the Phase I/II study for Duchenne muscular dystrophy has shown no severe adverse effects, which further supports the positive outlook. The company’s upcoming presentation at ASGCT is anticipated to provide more data reinforcing the safety profile of SGT-003. Despite potential regulatory uncertainties due to leadership changes at the FDA, Solid’s early-stage pipeline and innovative capsid library are seen as undervalued assets that could drive future growth or attract business development opportunities.
In another report released today, Citizens JMP also maintained a Buy rating on the stock with a $15.00 price target.
Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SLDB in relation to earlier this year.